Fiche centre
UI Healthcare Mission Cancer and Blood - Fort Dodge
Fort Dodge — United States
Essais liés7clinical trials
VilleFort Dodgelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03984448
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING |
| Biospecimen Collection | SEP | Phase 2/3 | NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Biospecimen Collection | Cancer | Phase 2/3 | NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | RECRUITING |
| Anastrozole | Cancer | Phase 3 | NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | RECRUITING |